市场调查报告书
商品编码
1308363
军团菌检测市场:2023-2028年全球行业趋势、份额、规模、增长、机会及预测Legionella Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年,全球军团菌检测市场规模达到2.855亿美元。展望未来,IMARC集团预计到2028年,该市场规模将达到4.556亿美元,2023-2028年期间的年复合增长率(CAGR)为8%。
军团菌是一种影响下呼吸道的感染,可导致重症肺炎、庞蒂亚克热和类似流感症状的疾病。其检测有助于确定血液、尿液和痰中是否存在细菌或抗原。目前有多种检测方法可用于诊断军团菌病,包括尿抗原、配对血清学、聚合酶链反应(PCR)、直接荧光抗体(DFA)染色和下呼吸道分泌物培养。根据检测结果,通常对患者使用大环内酯类、喹诺酮类、四环素、强力霉素、米诺环素、三甲双胍和其他抗生素治疗。
50岁以上的成年人更容易感染军团菌。因此,全球老年人口的增加是积极影响市场的主要因素之一。此外,吸烟和患有癌症、糖尿病、肾病、人类免疫缺陷病毒(HIV)或其他慢性疾病的人数不断增加,这些人面临感染和住院的风险。由于军团菌的死亡率很高,因此对其有效诊断检测和治疗的需求也在增加。此外,军团菌主要存在于不同的自然和人工水生环境中,如冷却塔、呼吸治疗设备、喷泉、喷雾装置、水疗池以及酒店、家庭和工厂的供水系统。因此,许多国家的卫生机构正在制定有效的水安全计划(WSP),以尽量减少军团菌在水中的扩散。这反过来又增加了对工作场所建筑中军团菌检测的需求,以符合相关法规。此外,近期针对社区获得性肺炎成人患者的诊断和治疗策略的临床试验也促进了市场的增长。
The global legionella testing market size reached US$ 285.5 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 455.6 Million by 2028, exhibiting a growth rate (CAGR) of 8% during 2023-2028.
Legionella is an infection affecting the lower respiratory tract, which can lead to severe pneumonia, Pontiac fever, and illness with flu-like symptoms. Its testing helps to identify the existence of bacteria or antigens in blood, urine, and sputum. Presently, various testing methods are available to diagnose Legionella disease, including urinary antigen, paired serology, Polymerase Chain Reaction (PCR), Direct Fluorescent Antibody (DFA) stain, and culture of lower respiratory secretions. As per the testing results, macrolides, quinolones, tetracycline, doxycycline, minocycline, trimethoprim and other antibiotic treatments are usually administered to patients.
Adults over the age of 50 years are more likely to develop Legionella. Consequently, the increasing geriatric population worldwide represents one of the major factors influencing the market positively. Moreover, the rising number of individuals who smoke and have cancer, diabetes, kidney disease, human immunodeficiency virus (HIV), or other chronic illnesses are at the risk of infection and hospitalization. Since the mortality rate of Legionella is high, there is an increase in the demand for its effective diagnostic tests and treatments. Besides this, Legionella-causing bacteria are majorly found in different natural and artificial aquatic environments, such as cooling towers, respiratory therapy equipment, fountains, misting devices, spa pools, and water systems in hotels, homes, and factories. As a result, health agencies of numerous countries are developing an effective water safety plan (WSP) to minimize the proliferation of Legionella in the water. This, in turn, is escalating the demand for Legionella testing in workplace buildings to comply with the legislation. Furthermore, recent clinical trials on diagnostic and treatment strategies for adult patients with community-acquired pneumonia are contributing to the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global legionella testing market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on application and end user.
Water Testing
Microbial Culture
DFA Stain
PCR
Others
IVD Testing
Blood Culture
Urine Antigen Test
DFA Stain
PCR
Others
Diagnostic Laboratories
Hospital and Clinics
Others
Europe
Italy
Germany
France
Spain
United Kingdom
Russia
Others
North America
United States
Canada
Asia Pacific
China
Japan
Australia
South Korea
Indonesia
Singapore
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, Becton, Dickinson and Company, BioMerieux SA, Bio-Rad Laboratories Inc, Eiken Chemical Co. Ltd, Quidel Corporation, Takara Bio Inc., and Thermo Fisher Scientific Inc.